Evidence map›Paper›PMID 42098542›Full record

ReviewCNS drugs2026

Restorative or Disruptive? Effects of Antidepressants on Sleep Architecture in Depression.

Anna Szynkarek, Weronika Tyrybon, Maria Karcz, Klaudia Lustyk, Kinga Sałaciak, Karolina Pytka

Abstract readReview
PubMed Publisher
In one paragraph

Review in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna SzynkarekLaboratory of Experimental Neuropharmacology, Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St., 30-688, Kraków, Poland.
Weronika TyrybonLaboratory of Experimental Neuropharmacology, Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St., 30-688, Kraków, Poland.
Maria KarczFaculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Klaudia LustykLaboratory of Experimental Neuropharmacology, Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St., 30-688, Kraków, Poland.
Kinga SałaciakLaboratory of Experimental Neuropharmacology, Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St., 30-688, Kraków, Poland. kinga.salaciak@uj.edu.pl.ORCID 0000-0002-0507-1989
Karolina PytkaLaboratory of Experimental Neuropharmacology, Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St., 30-688, Kraków, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sleep disturbances frequently occur in depression, stemming from the pathophysiology of the disorder and its pharmacological treatment. Antidepressants exert intricate, class-specific effects on sleep architecture, influencing rapid eye movement (REM) latency and density, slow-wave sleep, and overall sleep quality. Although some of these changes might contribute to the therapeutic efficacy, they can also worsen sleep problems and cause daytime fatigue. Recent findings suggest that alterations in REM sleep may serve as potential indicators of antidepressant response, particularly for drugs that strongly affect sleep architecture. Among antidepressants, selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors most consistently suppress REM sleep and fragment sleep continuity, whereas drugs with receptor-modulating or melatonergic properties, such as agomelatine or mirtazapine, tend to preserve restorative sleep stages and improve circadian alignment. Understanding how antidepressants influence sleep structure and related neurobiological mechanisms is essential for optimizing treatment strategies. Enhancing sleep quality may not only potentiate the therapeutic effects of antidepressants but also contribute to overall patient outcomes. Implementing standardized sleep assessment methods would facilitate research on the effects of long-term antidepressant treatment and help clinicians tailor treatments based on antidepressant efficacy, sleep-related impact, and patient-specific symptoms.

Indexed as

Antidepressive AgentsDepressionSleepSleep Wake DisordersAnimalsHumansSleep, REMAntidepressive Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.